# A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

> **NCT02509598** · PHASE2 · COMPLETED · sponsor: **Cardinal Health 414, LLC** · enrollment: 24 (actual)

## Conditions studied

- Rhabdomyosarcoma
- Melanoma

## Interventions

- **DRUG:** Tc99m tilmanocept
- **DRUG:** Vital Blue Dye (optional)
- **PROCEDURE:** Lymph Node Mapping

## Key facts

- **NCT ID:** NCT02509598
- **Lead sponsor:** Cardinal Health 414, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2019-03-06
- **Final completion:** 2019-03-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509598, "A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02509598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*